A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease

NCT04655807 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor Decision.

Conditions

Crohn Disease

Interventions

DRUG: JNJ-64304500
DRUG: Placebo
DRUG: Adalimumab
DRUG: Ustekinumab

Sponsor

Janssen Research & Development, LLC